Michel Lenonetti is a Senior Scientist in immunology and team leader at Atomic Energy Commission (CEA) with over 20 years of experience in technological and industrial research collaborations. Michel’s extensive research on the induction mechanisms of immune response led him to the breakthrough innovation known as IVI technology and its further derivation into a fully human antibody platform. Dr. Leonetti holds a PhD in Immunology from University Paris XI is author of over 40 peer reviewed articles and patents.
Immune Response, immunity